awmsg logo



daclatasvir (Daklinza®)


Reference No. 1464

Publication date:
20/05/2015


Appraisal information

daclatasvir (Daklinza®) 30 mg film-coated tablet
daclatasvir (Daklinza®) 60 mg film-coated tablet


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Infections
NMG meeting date: 25/02/2015
AWMSG meeting date: 25/03/2015
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 0615
Ministerial ratification: 15/05/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA364) NICE GUIDANCE ISSUED NOVEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Daclatasvir (Daklinza®) in combination with other medicinal products is recommended as an option for restricted use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adults. Use should be restricted to patients with significant fibrosis (METAVIR score ≥ F3) or compensated cirrhosis. Daclatasvir (Daklinza®) in combination with other medicinal products is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download